Comparative Pharmacology
Head-to-head clinical analysis: SEYSARA versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEYSARA versus TETRACYN.
SEYSARA vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
100 mg orally once daily with food.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic